When a Stage 4 Diagnosis Changes Everything
When Joanne Ferrari-Mautino went in for an X-ray, she knew something wasn’t right.
“I’ve been a nurse for 20 years,” she said. “I knew it was not a good sign.”
What started as a persistent cough quickly turned into something far more serious. Within days, Joanne was told she had Stage 4 non-small cell lung cancer—and a life expectancy of just 18 months to two years.
In that moment, everything changed.
She had a teenage son. A partner. A life she loved in her small Connecticut town. And suddenly, she was facing a diagnosis that felt overwhelming and uncertain.
Finding Answers Through Biomarker Testing
But Joanne’s story didn’t end there.
Further testing revealed something critical—a genetic mutation known as a ROS1 fusion, a rare driver of lung cancer. That one piece of information changed everything about her treatment path.
She was referred to Memorial Sloan Kettering Cancer Center, where she met Alexander Drilon, a physician who specializes in ROS1 lung cancer treatment.
Instead of standard chemotherapy, Joanne was able to begin targeted therapy for Stage 4 lung cancer—a treatment designed specifically for the genetic mutation driving her cancer.
What followed felt, in her words, like a miracle.
“I live a normal life. Sometimes people don’t even know I have cancer.”
A Second Story of Strength
Joanne’s experience is not the only one.
Anthony Valente, 63, was also diagnosed with advanced lung cancer after tumors were discovered during a routine exam. Initial treatment worked for a time—but eventually, the cancer began to grow again.
At that point, he was offered something different: a clinical trial for a next-generation ROS1 targeted therapy.
After starting treatment, he saw rapid improvement.
“The cancer shrunk and shrunk and shrunk. I actually feel better now than before I had cancer.”
For Anthony, it wasn’t just the treatment that made a difference—it was also the support around him. His wife of 40 years stood beside him through every step, and the care team helped guide him through difficult decisions.
Why These Stories Matter
Joanne and Anthony’s stories highlight something incredibly important for patients with Stage 4 lung cancer:
The right treatment can change everything.
Advances in targeted therapy for lung cancer, including newer drugs like Repotrectinib, Taletrectinib, and Zidesamtinib, are helping patients live longer with fewer side effects.
But these treatments are only possible when patients:
- Receive biomarker testing
- Get connected to the right specialists
- Access leading cancer centers and clinical trials
And for many patients, that access is the biggest challenge.
The Reality Many Patients Face
Too often, patients are not missing options—they are missing access.
Delays in referrals, lack of awareness about ROS1 lung cancer treatment, and the burden of travel can prevent patients from reaching the care that could extend their lives.
Time matters—especially with advanced cancer.
How Stage4Hope Helps Patients Like Joanne and Anthony
At Stage4Hope, we are focused on one mission:
Helping patients with Stage 4 cancer access life-saving care—faster.
We help patients:
- Connect with leading cancer centers
- Explore targeted therapy and clinical trial options
- Navigate complex treatment decisions
- Access travel support when distance is a barrier
👉 Learn more about how we support patients: https://stage4hope.org
If you or a loved one has been diagnosed with Stage 4 lung cancer, especially with a known mutation like ROS1, getting to the right place quickly can make all the difference.
👉 Explore resources and patient support: https://stage4hope.org/resources
Healthcare providers and partners can refer patients directly to Stage4Hope for travel assistance grants, helping reduce the financial burden of traveling for treatment or a second opinion.
👉 Refer a patient or partner with us: https://stage4hope.org
References:
